China's Senaparib Goes Ex-China as Radiopharma and Medtech M&A Surges: IMPACT Licenses Its PARP Inhibitor to Pharmanovia for up to EUR 423.5M, Curium Buys Lantheus for up to $8B, and KKR Takes Integer Private for $5.7B

The week's cross-border licensing ran through a single verified transaction, but a substantial one: IMPACT Therapeutics' out-license of senaparib to Pharmanovia extends the now-familiar pattern of Chinese biotechs monetizing approved or late-stage assets in Western and adjacent markets. Around it, US dealmaking was dominated by consolidation rather than innovation licensing. Curium agreed to buy Lantheus for up to about $8.0B to build a radiopharmaceutical champion spanning PYLARIFY (PSMA PET imaging), DEFINITY (cardiac ultrasound) and Neuraceq (amyloid PET), and KKR agreed to take Integer Holdings - a contract manufacturer of components for cardiac, neuromodulation and pain devices - private for about $5.7B. Both are picks-and-shovels plays on imaging and device supply rather than single-drug bets.

The week's loudest story was a deal that did not happen: reports that AstraZeneca had explored a roughly $400B combination with Bristol Myers Squibb were met with a sharp negative reaction, with AstraZeneca shares falling about 8% - some $22B of market value - on antitrust and integration concerns before the talks appeared to stall. That mega-scale hesitation keeps mid-size acquisitions and cross-border licensing - including China-out deals like senaparib - as the more reliable route to pipeline expansion. On the science side, Lilly's second Breakthrough Therapy designation for the KRAS G12C inhibitor olomorasib and Pfizer's positive Phase 3 for the oral JAK3/TEC inhibitor LITFULO in vitiligo show KRAS oncology and autoimmune dermatology - two of the most active China-out licensing categories - continuing to generate Western-market validation.

August 3, 2026 - Lilly's KRAS G12C Inhibitor Olomorasib Wins a Second FDA Breakthrough Therapy Designation, in Previously Treated KRAS G12C-Mutant Advanced Pancreatic Cancer

The FDA granted Breakthrough Therapy designation to olomorasib (Lilly) as monotherapy for adults with advanced pancreatic cancer who have a KRAS G12C mutation and have received at least one prior systemic therapy. Olomorasib is an investigational, potent, highly selective next-generation covalent inhibitor of KRAS G12C. This is the drug's second Breakthrough Therapy designation: the FDA previously granted it in combination with anti-PD-1 therapy KEYTRUDA (pembrolizumab) for first-line locally advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation and PD-L1 expression of at least 50%.

BD Implication: KRAS G12C is a validated but crowded target, and a next-generation inhibitor earning breakthrough status in a hard-to-treat solid tumor like pancreatic cancer signals that differentiation on selectivity, brain penetration and combinability - not merely hitting the target - is what still commands regulatory and commercial attention. For sponsors of China-origin KRAS and broader RAS-pathway programs, this is the profile Western buyers are underwriting, and it maps directly to Opportunity-Board mandates #8 (KRAS G12V) and #23 (MEK-RAF / KRAS-CYP A small molecules and molecular glues).

July 30, 2026 - Pfizer's Oral JAK3/TEC Inhibitor LITFULO (ritlecitinib) Posts Positive Phase 3 Topline in Nonsegmental Vitiligo

Pfizer reported that two pivotal Phase 3 studies of LITFULO (ritlecitinib) - TRANQUILLO (607 adolescents and adults dosed at 50 mg) and TRANQUILLO 2 (1,567 adults dosed at 50 mg or 100 mg) - met their co-primary endpoints, showing statistically significant improvements in facial (F-VASI75) and total-body (T-VASI50) repigmentation versus placebo at week 52. It is described as the largest Phase 3 program to date for an oral systemic therapy in nonsegmental vitiligo. Ritlecitinib is an oral covalent inhibitor selective for JAK3 and the TEC kinase family; Pfizer plans global regulatory filings, with full efficacy data to follow at scientific meetings.

BD Implication: Vitiligo is fast becoming a proving ground for autoimmune mechanisms - the same indication where argenx paid about $2.2B for Forte's anti-CD122 antibody FB102 last week, now with an oral JAK3/TEC inhibitor delivering pivotal repigmentation data. For China-origin JAK, TYK2 and dual TYK2/JAK programs (Board mandate #26), a positive large Phase 3 on a validated F-VASI endpoint sets the efficacy and safety bar Western partners will benchmark against, and confirms dermatologic autoimmune disease as a category where both oral small molecules and antibodies can find buyers.

July 31, 2026 - The FLAMES Phase 3 Dataset Behind the Senaparib China-Out License

The clinical foundation for IMPACT Therapeutics' out-license of senaparib to Pharmanovia is the Phase 3 FLAMES trial (NCT04169997), in which senaparib as first-line maintenance monotherapy significantly improved progression-free survival versus placebo in patients with newly diagnosed advanced ovarian, fallopian tube or primary peritoneal cancer who had responded to platinum-based chemotherapy. Those data supported China's NMPA approval of senaparib as first-line maintenance monotherapy, making it a commercially approved asset rather than a pipeline candidate at the time of the ex-China license.

BD Implication: An NMPA-approved PARP inhibitor licensing into Europe and adjacent markets illustrates the maturing shape of China-out deals - not just early-stage assets sold to large pharma, but approved products partnered with commercial-stage Western specialty players for ex-China territories. For BD readers, senaparib is a template for how a domestically approved oncology asset can be structured into upfront, milestone and royalty economics through a regional licensee, and it keeps DNA-damage-response oncology on the sourcing radar alongside the KRAS programs above.

Validation notes: The IMPACT-Pharmanovia senaparib terms (up to EUR 423.5M; royalties up to the mid-twenties percent; 66 countries) are as disclosed in IMPACT's July 31 announcement. The Curium-Lantheus ($102.50/share cash plus up to $12.00/share in CVRs; up to about $8.0B) and KKR-Integer ($127.00/share; about $5.7B enterprise value) figures are the parties' stated terms. Olomorasib's Breakthrough Therapy designation and prior designation are per Lilly's August 3 disclosure. LITFULO Phase 3 figures (TRANQUILLO n=607; TRANQUILLO 2 n=1,567; F-VASI75 and T-VASI50 at week 52) are company-reported. The reported AstraZeneca-Bristol Myers merger discussions were not confirmed as a definitive agreement and are labeled as reported talks. Senaparib FLAMES data reflect the trial's published primary-endpoint result and the basis for NMPA approval.